Cargando…
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731927/ https://www.ncbi.nlm.nih.gov/pubmed/36509358 http://dx.doi.org/10.1016/j.jinf.2022.12.003 |
| _version_ | 1784846010895302656 |
|---|---|
| author | Hannawi, Suad Saifeldin, Linda Abuquta, Alaa Alamadi, Ahmad Mahmoud, Sally A. Li, Jian Chen, Yuanxin Xie, Liangzhi |
| author_facet | Hannawi, Suad Saifeldin, Linda Abuquta, Alaa Alamadi, Ahmad Mahmoud, Sally A. Li, Jian Chen, Yuanxin Xie, Liangzhi |
| author_sort | Hannawi, Suad |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9731927 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97319272022-12-09 Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial Hannawi, Suad Saifeldin, Linda Abuquta, Alaa Alamadi, Ahmad Mahmoud, Sally A. Li, Jian Chen, Yuanxin Xie, Liangzhi J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-12-09 /pmc/articles/PMC9731927/ /pubmed/36509358 http://dx.doi.org/10.1016/j.jinf.2022.12.003 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Hannawi, Suad Saifeldin, Linda Abuquta, Alaa Alamadi, Ahmad Mahmoud, Sally A. Li, Jian Chen, Yuanxin Xie, Liangzhi Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial |
| title | Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial |
| title_full | Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial |
| title_fullStr | Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial |
| title_full_unstemmed | Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial |
| title_short | Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial |
| title_sort | safety and immunogenicity of a bivalent sars-cov-2 protein booster vaccine, sctv01c in adults previously vaccinated with inactivated vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731927/ https://www.ncbi.nlm.nih.gov/pubmed/36509358 http://dx.doi.org/10.1016/j.jinf.2022.12.003 |
| work_keys_str_mv | AT hannawisuad safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial AT saifeldinlinda safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial AT abuqutaalaa safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial AT alamadiahmad safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial AT mahmoudsallya safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial AT lijian safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial AT chenyuanxin safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial AT xieliangzhi safetyandimmunogenicityofabivalentsarscov2proteinboostervaccinesctv01cinadultspreviouslyvaccinatedwithinactivatedvaccinearandomizeddoubleblindplacebocontrolledphase12clinicaltrial |